Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 20

[News]

Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

More... (http://www.news-medical.net/news/20140407/Eli-Lilly-presents-early-stage-data-from-several-targeted-cancer-therapies-at-AACR-2014.aspx)